glp 1 and seizures Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy associated comorbidities GLP-1 diabetes drugs linked to

Analysis of clinical secondary endpoints Fishers exact test was used to compare categorical variables (as short-term neonatal morbidity) between NAC- and placebo arms

In their prescribing information, both companies warn about potentially severe gastrointestinal side effects and advise against using these medications in people who already have severe gastroparesis

200 Poor neuromuscular control, often due to inadequate proprioception or coordination, can result in delayed muscle activation and improper joint alignment during movements

Clinical trials consistently show that people lose 12 to 18 percent of their body weight when taking these medications along with lifestyle changes

Studied for the KPV tripeptide's role in inflammatory signalling pathways and immune responses